Vanda Pharmaceuticals, Inc.

How big is Vanda Pharmaceuticals, Inc.?

As of Jun 18, Vanda Pharmaceuticals, Inc. has a market capitalization of 264.62 million and reported net sales of 201.35 million with a net profit of -44.24 million over the latest four quarters. Shareholder's funds are 538.55 million, and total assets amount to 656.20 million.

As of Jun 18, Vanda Pharmaceuticals, Inc. has a market capitalization of 264.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 201.35 million, while the sum of net profit for the same period is -44.24 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 538.55 million, and total assets amount to 656.20 million.

What does Vanda Pharmaceuticals, Inc. do?

Vanda Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for unmet medical needs. As of March 2025, it reported net sales of $50 million and a net loss of $29 million, with a market cap of $264.62 million.

Overview:<BR>Vanda Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 50 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 264.62 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.66<BR>- Return on Equity: -8.65%<BR>- Price to Book: 0.52<BR><BR>Contact Details:<BR>- Address: 2200 Pennsylvania Ave NW Ste 300E, WASHINGTON DC: 20037-1754<BR>- Tel: 1 202 7343400<BR>- Fax: 1 202 2961450<BR>- Website: http://www.vandapharma.com/

Should I buy, sell or hold Vanda Pharmaceuticals, Inc.?

Who are in the management team of Vanda Pharmaceuticals, Inc.?

As of March 2022, Vanda Pharmaceuticals, Inc.'s management team includes H. Thomas Watkins (Independent Chairman), Dr. Mihael Polymeropoulos (President and CEO), and several Independent Directors: Phaedra Chrousos, Richard Dugan, Stephen Mitchell, and Anne Ward. The team features a blend of executive leadership and independent governance.

As of March 2022, the management team of Vanda Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. H. Thomas Watkins, who serves as the Independent Chairman of the Board.<BR>- Dr. Mihael Polymeropoulos, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Phaedra Chrousos, who is an Independent Director.<BR>- Mr. Richard Dugan, who is also an Independent Director.<BR>- Dr. Stephen Mitchell, who serves as an Independent Director.<BR>- Ms. Anne Ward, who is another Independent Director.<BR><BR>In summary, the management team comprises a mix of executive leadership and independent directors, highlighting a diverse governance structure.

Is Vanda Pharmaceuticals, Inc. overvalued or undervalued?

As of May 8, 2024, Vanda Pharmaceuticals is considered overvalued and has been downgraded to a risky valuation grade, with poor financial metrics and significant underperformance compared to the S&P 500.

As of 8 May 2024, the valuation grade for Vanda Pharmaceuticals, Inc. has moved from expensive to risky, indicating a significant downgrade in its perceived value. The company is currently considered overvalued based on its financial metrics, particularly with a Price to Book Value of 0.53, an EV to EBIT of 0.89, and an EV to EBITDA of 1.00. Compared to peers, Vanda's valuation ratios are less favorable, with Lexicon Pharmaceuticals, Inc. showing a P/E of -3.5278 and an EV to EBITDA of -2.8670, highlighting a relative weakness in Vanda's financial standing.<BR><BR>The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -5.64% compared to the index's 12.22%, and a staggering decline of -54.62% over the past three years versus the S&P's 70.41% gain. This stark contrast reinforces the view that Vanda Pharmaceuticals is overvalued in the current market environment.

Is Vanda Pharmaceuticals, Inc. technically bullish or bearish?

As of September 11, 2025, Vanda Pharmaceuticals' technical trend is neutral with mixed signals, showing a mildly bullish MACD but overall underperformance compared to the S&P 500, with year-to-date returns of -5.64% versus 12.22% for the index.

As of 11 September 2025, the technical trend for Vanda Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with a mix of indicators showing both bullish and bearish signals. The MACD is mildly bullish on both weekly and monthly time frames, while the daily moving averages also indicate a mildly bullish trend. However, the KST, Dow Theory, and OBV are all mildly bearish on the weekly and monthly time frames, suggesting underlying weakness. The Bollinger Bands show a sideways trend weekly but bearish monthly. <BR><BR>In terms of performance, Vanda Pharmaceuticals has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.64% versus the S&P 500's 12.22%, and a one-year return of -8.69% compared to 17.14% for the index.